Rofecoxib does not inhibit the growth of transformed cells in vitro

Gastrointestinal Oncology

Volumn 4, Issue 2-3, 2002, Pages 71-75

  Averbuch, M ^a   Kazanov, D ^a   Keret, D ^a   Pick, M ^a   Strier, L ^a   Dvori Sobol, H ^a   Deutsch, V ^a   Kunick, T ^a   Halpern, Z ^a   Arber, N ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

COX 2 inhibitor; In vitro; Rofecoxib; Sulindac; Transformed cells

Indexed keywords

CYCLIN D1; CYCLINE; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; PROTEIN BAK; PROTEIN BCL 2; ROFECOXIB; SULINDAC SULFIDE;

ANIMAL CELL; APOPTOSIS; ARACHIDONIC ACID METABOLISM; CANCER INHIBITION; CELL GROWTH; CELL TRANSFORMATION; CENP C GENE; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; GASTROINTESTINAL TOXICITY; GENE; GROWTH INHIBITION; HUMAN; INTESTINE EPITHELIUM CELL; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN DETERMINATION; RAT;

EID: 0036663922     PISSN: 1475956X     EISSN: None     Source Type: Journal    
DOI: 10.1080/1475956021000041112     Document Type: Conference Paper

References (25)

1. Parkin, D.M., Pisani, P. and Ferlay, J. (1999) "Global cancer statistics", CA Cancer J. Clin. 49, 33-64.
2. Peeters, M. and Haller, D.G. (1999) "Therapy for early stage colorectal cancer", Oncology 13, 307-315.
3. Cole, P. and Sateren, W. (1994) "The evolving picture of cancer in America", JNCI 87, 59.
4. Strul, H. and Arber, N. (2000) "NSAIDs prevent colorectal cancer: The role of the super aspirins", IMAJ 2, 322-324.
5. DuBois, R.N., Giardiello, F.M. and Sammalley, W.E. (1996) "NSAIDs, eicosanoids, and colorectal cancer prevention", Gastroenterol. Clin. N. Am. 25, 773-791.
6. Muscat, J.E., Stellman, S.D. and Wynder, E.L. (1994) "Nonsteroidal anti-inflammatory drugs and colorectal cancer", Cancer 74, 1847-1854.
7. Wolfe, M.M., Lichtenstein, D.R. and Singh, G. (1999) "Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs", N. Engl. J. Med. 340, 1888-1899.
8. Hla, T. and Neilson, K. (1992) "Human cyclooxygenase-2 cDNA", Proc. Natl Acad. Sci. USA 89, 7384-7388.
9. Eberhart, C.E., Coffey, R.J., Radhika, A., Giardiello, F.M., Ferrenbach, S. and DuBois, R.N. (1994) "Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas", Gastroenterology 107, 1183-1188.
10. Reddy, B.S., Rao, C.V. and Seibert, K. (1996) "Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis", Cancer Res. 56, 4566-4571.
11. Oshima, M., Dinchuk, J.E., Kargman, S.L., Oshima, H., Hancock, B., Kwong, E., et al. (1996) "Suppression of intestinal polyposis in APC knockout mice by inhibition of cyclooxygenase 2 [COX-2]", Cell 87, 803-809.
12. Arber, N., Sutter, T., Miyake, M., Kahn, S., Venkatraj, V.S., Sobrino, A., et al. (1996) "Increased expression of cyclin D1 and the Rb tumor suppressor gene in c-K-ras transformed rat enterocytes", Oncogene 12, 1903-1908.
13. Arber, N., Deutsch, V., Pick, M., Kaznov, D., Rattan, J., Moskowitz, M., et al. (1999) "Ras transformed enterocytes overexpressing bak have an increased apoptotic tendency", Gastroenterology 117, A372.
14. Arber, N., Kazanov, D., Meltzer, E., Brill, S., Rattan, J. and Halpern, Z. (1999) "Overexpression of cyclin D1 in normal enterocytes (IEC18) increases proliferation and inhibits apoptosis", Gastroenterology 117, A372.
15. Kaznov, D., Stem, B., Pick, M., Deutsch, V.R., Brazowski, E., Shapira, I., et al. (2000) "Down regulation of bak expression in normal enterocytes by anti-sense construct results in malignant transformation", Gastroentrology 119, A442.
16. Kazanov, D., Stem, B., Pyerin, W., Boecher, O., Strul, H., Moshkowitz, M., et al. (2001) "CENP-C: An oncogene or tumor suppressor gene? A possible new tumor marker", Gastroenterology 119, A299.
17. Arber, N., Han, E.K.H., Sgambato, A., Piazza, G.A., Delohery, T.M., Begemann, M., et al. (1997) "A K-ras oncogene increases resistance to sulindac sulfide induced apoptosis in rat enterocytes", Gastroenterology 113, 1892-1900.
18. Kazanov, D., Liberman, E., Strier, L., Umansky, M., Pick, M., Deutch, V., et al. (2002) "Celecoxib inhibits the growth of transformed but not normal cells", Gastroenterology 124, A4.
19. Stern, B., Kaznov, D., Strier, L., Liberman, E., Shapira, I., Rattan, J., et al. (2001) "The mechanism of drug resistancy to sulindac sulfone (Aptosyn™) and nimesulid (N)", Gastroenterology 122, A668.
20. Quaroni, A. and Isselbacher, K.J. (1981) "Cytotoxic effects and metabolism of benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene in duodenal and ileal epithelial cell cultures", JNCI 67, 1353-1362.
21. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., et al. (2000) "Comparison of upper gastrointestinal toxicity of MK-966 and naproxen in patients with rheumatoid arthritis", N. Engl. J. Med. 343, 1520-1528.
22. Averbuch, M., Kazanov, D., Liberman, E., Gertner, M., Strier, L., Moskowitz, M., et al. (2002) "Rofecoxib (Vioxx™) and sulindac prevent all stages of tumor formation in an animal model", Gastroenterology 124, A233.
23. Steinbach, G., Lynch, P.M., Phillips, R.K., Wallace, M.H., Hawk, E., Gordon, G.B., et al. (2000) "The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis", N. Engl. J. Med. 342, 1946-1952.
24. Baron, L., Strul, H., Dagani, Y., Hallack, A., Halpern, Z., Arber, N., "Rofecoxib reduces polyp recurrence in polyposis patients". Cancer Research 2002, submitted.
25. Giardiello, F.M., Hamilton, S.R., Krush, A.J., Piantadosi, S., Hylind, L.M., Celano, P., et al. (1993) "Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis", N. Engl. J. Med. 328, 1313-1316.